Benefits and harm of paracetamol and ibuprofen in combination for post‐operative pain: Pre‐planned subgroup analyses of the multicenter, randomized PANSAID trial. Issue 2 (16th November 2019)

• Record Type: Journal Article
• Authors: Thybo, Kasper H.; Hägi‐Pedersen, Daniel; Wetterslev, Jørn; Dahl, Jørgen B.; Jakobsen, Janus C.; Pedersen, Niels Anker; Jakobsen, Karina; Bülow, Hans Henrik; Ibsen, Louise; Overgaard, Søren; Mathiesen, Ole
• Is Part Of: Acta anaesthesiologica scandinavica. Volume 64:Issue 2(2020:Feb.)
• Page Start: 245
• Page End: 253
• Publication Date: 2019-11-16
• Subjects: Anesthesiology -- Periodicals; Critical care medicine -- Periodicals; 617.9605
• DOI: 10.1111/aas.13496
• Languages: English
• ISSNs: 0001-5172

Abstract

Abstract : Background: The "Paracetamol and Ibuprofen in Combination" (PANSAID) trial showed that combining paracetamol and ibuprofen resulted in lower opioid consumption than each drug alone and we did not find an increase in risk of harm when using ibuprofen vs paracetamol. The aim of this subgroup analysis was to investigate the differences in benefits and harms of the interventions in different subgroups. We hypothesized that the intervention effects would differ in subgroups with different risk of pain or adverse events. Methods: In these pre‐planned subgroup analyses of the PANSAID trial population, we assessed subgroup heterogeneity in intervention effects between (a) subgroups (sex, age, use of analgesics, American Society of Anesthesiologists (ASA) score, and type of anesthesia) and morphine consumption, and (b) subgroups (sex, age, use of non‐steroidal anti‐inflammatory drugs (NSAIDs), and ASA score) and serious adverse events. Results: Test of interaction between age and the pairwise comparison between paracetamol 1 g vs paracetamol 0.5 g + ibuprofen 200 mg ( P = .009) suggested lower morphine consumption in patients >65 years. However, post hoc analyses of related outcomes showed no interaction for this pairwise comparison. All other tests of interaction regarding both benefit and harm were not statistically significant. Conclusion: These pre‐planned subgroup analyses did not suggest that patients in the investigated subgroups benefitted differently from a basic non‐opioid analgesic regimen consisting of paracetamol and ibuprofen. Further, there was no evidence of subgroup heterogeneity regarding harm and use of ibuprofen. Because of reduced statistical power in subgroup analyses, we cannot exclude clinically relevant subgroup heterogeneity.